Literature DB >> 23212461

Duration of treatment for candidemia and risk for late-onset ocular candidiasis.

O Blennow1, L Tallstedt, B Hedquist, B Gårdlund.   

Abstract

PURPOSE: Few reports have been published on the optimal duration of treatment of ocular candidiasis. We have investigated the incidence of late-onset Candida chorioretinitis and endophthalmitis in patients with candidemia who did not initially receive an ophthalmologic examination. The aim was to determine the duration of initial antifungal treatment that may be sufficient to avoid this complication.
METHODS: This was a long-term follow-up study of 144 patients with candidemia who survived for at least 60 days after the onset of candidemia. The frequency of early- and late-onset ocular complications due to candida infection and factors associated with ocular candidiasis were investigated.
RESULTS: Fundoscopy was performed on 60 patients, revealing 12 cases of ocular candida infection (20 %). Risk factors were infection with Candida albicans compared to other Candida species (p = 0.021) and surgery due to solid tumor (p = 0.004). Only one case of late-onset ocular candidiasis occurred among the 84 candidemic patients who did not receive an initial ophthalmologic examination. For unknown reasons, this patient had received only 2 days of systemic antifungal treatment initially.
CONCLUSIONS: No case of late-onset ocular candidiasis was detected in unexamined patients who received at least 14 days of antifungal treatment. Based on our results, it would appear that the recommended 2 weeks of treatment after the first negative blood culture are sufficient to avoid late-onset complications due to undiscovered Candida chorioretinitis in patients surviving for more than 60 days after the onset of candidemia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23212461     DOI: 10.1007/s15010-012-0369-8

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  12 in total

1.  Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America.

Authors:  Leonard A Mermel; Michael Allon; Emilio Bouza; Donald E Craven; Patricia Flynn; Naomi P O'Grady; Issam I Raad; Bart J A Rijnders; Robert J Sherertz; David K Warren
Journal:  Clin Infect Dis       Date:  2009-07-01       Impact factor: 9.079

2.  Epidemiology and management of candidaemia--a retrospective, multicentre study in five hospitals in the UK.

Authors:  C Chalmers; S Gaur; J Chew; T Wright; A Kumar; S Mathur; W Y Wan; I M Gould; A Leanord; A M Bal
Journal:  Mycoses       Date:  2011-05-25       Impact factor: 4.377

3.  Ocular manifestations of candidemia.

Authors:  Astrid M L Oude Lashof; Aniki Rothova; Jack D Sobel; Markus Ruhnke; Peter G Pappas; Claudio Viscoli; Haran T Schlamm; Iwona T Oborska; John H Rex; Bart Jan Kullberg
Journal:  Clin Infect Dis       Date:  2011-08-01       Impact factor: 9.079

4.  Fungal eye disease at a tertiary care center: the utility of routine inpatient consultation.

Authors:  Carey C Dozier; Ryan M Tarantola; Kim Jiramongkolchai; Sean P Donahue
Journal:  Ophthalmology       Date:  2011-05-06       Impact factor: 12.079

5.  Intraocular candidiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study.

Authors:  S P Donahue; C M Greven; J J Zuravleff; A W Eller; M H Nguyen; J E Peacock; M W Wagener; V L Yu
Journal:  Ophthalmology       Date:  1994-07       Impact factor: 12.079

6.  Experimental hematogenous endophthalmitis due to Candida: species variation in ocular pathogenicity.

Authors:  J E Edwards; J Z Montgomerie; K Ishida; J O Morrison; L B Guze
Journal:  J Infect Dis       Date:  1977-02       Impact factor: 5.226

7.  Spontaneous resolution of endogenous Candida endophthalmitis complicating intravenous hyperalimentation.

Authors:  A L Dellon; W J Stark; P B Chretien
Journal:  Am J Ophthalmol       Date:  1975-04       Impact factor: 5.258

8.  Candidaemia and risk of intraocular infection: a Danish hospital-based cohort study.

Authors:  Marianne Kirkegaard Karmisholt; Ulla Hjort; Lars Loumann Knudsen; Henrik Carl Schønheyder
Journal:  Scand J Infect Dis       Date:  2007-09-07

9.  Experimental hematogenous endophthalmitis caused by Candida albicans.

Authors:  J E Edwards; J Z Montgomerie; R Y Foos; V K Shaw; L B Guze
Journal:  J Infect Dis       Date:  1975-06       Impact factor: 5.226

Review 10.  Retinal lesions as clues to disseminated bacterial and candidal infections: frequency, natural history, and etiology.

Authors:  Libsen J Rodríguez-Adrián; Robert T King; Luis G Tamayo-Derat; John W Miller; Charles A Garcia; John H Rex
Journal:  Medicine (Baltimore)       Date:  2003-05       Impact factor: 1.889

View more
  8 in total

1.  [Not Available].

Authors:  Jf Arnould; R Le Floch
Journal:  Ann Burns Fire Disasters       Date:  2015-03-31

2.  Prevalence of, and risk factors for, hematogenous fungal endophthalmitis in patients with Candida bloodstream infection.

Authors:  Hideaki Kato; Yukihiro Yoshimura; Yoshihiro Suido; Kazuo Ide; Yoshifumi Sugiyama; Kasumi Matsuno; Hideaki Nakajima
Journal:  Infection       Date:  2018-06-29       Impact factor: 3.553

3.  Outcomes, impact on management, and costs of fungal eye disease consults in a tertiary care setting.

Authors:  Devon H Ghodasra; Kian Eftekhari; Ankoor R Shah; Brian L VanderBeek
Journal:  Ophthalmology       Date:  2014-08-10       Impact factor: 12.079

4.  A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade.

Authors:  A M Tortorano; A Prigitano; C Lazzarini; M Passera; M L Deiana; S Cavinato; C De Luca; A Grancini; G Lo Cascio; C Ossi; E Sala; M T Montagna
Journal:  Infection       Date:  2013-04-05       Impact factor: 3.553

5.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

6.  The incidence of endophthalmitis or macular involvement and the necessity of a routine ophthalmic examination in patients with candidemia.

Authors:  Takashi Ueda; Yoshio Takesue; Issei Tokimatsu; Taiga Miyazaki; Nana Nakada-Motokawa; Miki Nagao; Kazuhiko Nakajima; Hiroshige Mikamo; Yuka Yamagishi; Kei Kasahara; Shingo Yoshihara; Akira Ukimura; Koichiro Yoshida; Naomi Yoshinaga; Masaaki Izumi; Hiroshi Kakeya; Koichi Yamada; Hideki Kawamura; Kazuo Endou; Kazuaki Yamanaka; Mutsunobu Yoshioka; Kayoko Amino; Hiroki Ikeuchi; Motoi Uchino; Yoshitsugu Miyazaki
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

7.  Is routine ophthalmoscopy really necessary in candidemic patients?

Authors:  Antonio Vena; Patricia Muñoz; Belen Padilla; Maricela Valerio; Maria Isabel Sanchez; Mireia Puig-Asensio; Jesus Fortun; Mario Fernandez-Ruiz; Paloma Merino; Juan Emilio Losa; Ana Loza; Rosa Ana Rivas; Emilio Bouza
Journal:  PLoS One       Date:  2017-10-24       Impact factor: 3.240

Review 8.  Appropriate Duration of Intravenous Treatment of Candidemia and Timing of Step Down to Oral Therapy in Non-neutropenic Patients.

Authors:  Rita Wilson Dib; Ray Hachem; Anne-Marie Chaftari; Issam Raad
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-05-01       Impact factor: 2.576

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.